Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Protocol 4: Post-menopausal metabolic restoration Goal: Address menopausal weight gain and metabolic changes Stack: Tirzepatide: Standard protocol (addresses insulin resistance) Tesamorelin: 1-2mg daily (visceral fat) CJC-1295/Ipamorelin: 200mcg each before bed (body composition, bone density) Resistance training: 3-4x per week Adequate protein and calcium Duration: 12+ months, potentially ongoing Expected results: 25-45 pounds weight loss Reduced visceral fat Improved insulin sensitivity Better body composition Maintained bone density Why this works: Addresses multiple menopausal factors - insulin resistance, visceral fat, muscle loss, bone density
No evidence of genotoxic activity was found in either assay
Cardiovascular data on endpoints like MACE-3 or MACE-4 are presently not available yet, but an early meta-analysis demonstrated at least cardiovascular safety in patients with T2D treated with tirzepatide (78, 79)
Canada is the standout country, notably a high GDP-per capita and a high exposure to OOP spend, as well as a substantial prevalence of adults living with obesity
US$ 29.89
US$ 21.54
US$ 24.83
US$ 29.43
US$ 24.31
